20th Invitation to Manufacturers of Antituberculosis Medicines to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit (PQT)

Changes to the 20th TB EOI

Addition in Article 2, Section 3:

• Pretomanid, tablet, 200mg (footnote 13)

• Footnote 13: For use only as part of the BPaL regimen under operational research  conditions. The BPaL regimen comprises three components that are used as a package with pretomanid administered at 200 mg once daily, bedaquiline administered at 400 mg once daily for the first 2 weeks of treatment (days 1–14) and then 200 mg three times a week thereafter, and linezolid at 1200 mg per day.